Research ExplorerPublicationsOutcome of allogeneic stem cell transplantation for patients...

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

Standard

Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. / Hussein, Ayad Ahmed; Halkes, Constantijn M; Socié, Gérard; Tichelli, André; von dem Borne, Peter A; Schaap, Michel N P M; Foa, Robin; Ganser, Arnold; Dufour, Carlo; Bacigalupo, Andrea; Locasciulli, Anna; Aljurf, Mahmoud; Peters, Christina; Robin, Marie; van Biezen, Anja A; Volin, Liisa; De Witte, Theo; Marsh, Judith; Passweg, Jakob R; Kröger, Nicolaus-Martin; Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation.

In: BIOL BLOOD MARROW TR, Vol. 20, No. 9, 01.09.2014, p. 1448-50.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hussein, AA, Halkes, CM, Socié, G, Tichelli, A, von dem Borne, PA, Schaap, MNPM, Foa, R, Ganser, A, Dufour, C, Bacigalupo, A, Locasciulli, A, Aljurf, M, Peters, C, Robin, M, van Biezen, AA, Volin, L, De Witte, T, Marsh, J, Passweg, JR, Kröger, N-M & Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation 2014, 'Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation', BIOL BLOOD MARROW TR, vol. 20, no. 9, pp. 1448-50. https://doi.org/10.1016/j.bbmt.2014.05.028

APA

Hussein, A. A., Halkes, C. M., Socié, G., Tichelli, A., von dem Borne, P. A., Schaap, M. N. P. M., Foa, R., Ganser, A., Dufour, C., Bacigalupo, A., Locasciulli, A., Aljurf, M., Peters, C., Robin, M., van Biezen, A. A., Volin, L., De Witte, T., Marsh, J., Passweg, J. R., ... Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation (2014). Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. BIOL BLOOD MARROW TR, 20(9), 1448-50. https://doi.org/10.1016/j.bbmt.2014.05.028

Vancouver

Hussein AA, Halkes CM, Socié G, Tichelli A, von dem Borne PA, Schaap MNPM et al. Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. BIOL BLOOD MARROW TR. 2014 Sep 1;20(9):1448-50. https://doi.org/10.1016/j.bbmt.2014.05.028

Bibtex

@article{9bbc30bb30a64d4a8a3709cf828995f4,
title = "Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation",
abstract = "One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.",
author = "Hussein, {Ayad Ahmed} and Halkes, {Constantijn M} and G{\'e}rard Soci{\'e} and Andr{\'e} Tichelli and {von dem Borne}, {Peter A} and Schaap, {Michel N P M} and Robin Foa and Arnold Ganser and Carlo Dufour and Andrea Bacigalupo and Anna Locasciulli and Mahmoud Aljurf and Christina Peters and Marie Robin and {van Biezen}, {Anja A} and Liisa Volin and {De Witte}, Theo and Judith Marsh and Passweg, {Jakob R} and Nicolaus-Martin Kr{\"o}ger and {Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation}",
note = "Copyright {\textcopyright} 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = sep,
day = "1",
doi = "10.1016/j.bbmt.2014.05.028",
language = "English",
volume = "20",
pages = "1448--50",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation

AU - Hussein, Ayad Ahmed

AU - Halkes, Constantijn M

AU - Socié, Gérard

AU - Tichelli, André

AU - von dem Borne, Peter A

AU - Schaap, Michel N P M

AU - Foa, Robin

AU - Ganser, Arnold

AU - Dufour, Carlo

AU - Bacigalupo, Andrea

AU - Locasciulli, Anna

AU - Aljurf, Mahmoud

AU - Peters, Christina

AU - Robin, Marie

AU - van Biezen, Anja A

AU - Volin, Liisa

AU - De Witte, Theo

AU - Marsh, Judith

AU - Passweg, Jakob R

AU - Kröger, Nicolaus-Martin

AU - Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation

N1 - Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

AB - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.

U2 - 10.1016/j.bbmt.2014.05.028

DO - 10.1016/j.bbmt.2014.05.028

M3 - SCORING: Journal article

C2 - 24910382

VL - 20

SP - 1448

EP - 1450

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 9

ER -